Phase 2 Study With COmbination of Vemurafenib With Cobimetinib in B-RAF V600E/K Mutated Melanoma Patients to Normalize LDH and Optimize Nivolumab and Ipilimumab therapY
Latest Information Update: 05 Oct 2023
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary) ; Ipilimumab; Nivolumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms COWBOY
- 03 Jun 2020 Status changed from active, no longer recruiting to recruiting.
- 16 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 12 May 2017 Status changed from not yet recruiting to recruiting.